medigraphic.com
ISSN 2539-0859 (Electronic)
ISSN 0120-8411 (Print)
Asociación Colombiana de Otorrinolaringología y Cirugía de Cabeza y cuello, Maxilofacial y Estética Facial (ACORL)

2023, Number 4

<< Back Next >>

Acta de Otorrinolaringología CCC 2023; 51 (4)

Hearing loss in Vogt-Koyanagi-Harada syndrome: case report and literature review

Mora-Ramírez JC, Mejía-Perdigón LJ

Language: Spanish
References: 22
Page: 305-309
PDF size: 194.02 Kb.


ABSTRACT

Vogt-Koyanagi-Harada syndrome (VKHS) is a rare multisystemic granulomatous disease, characterized by severe bilateral panuveitis and serous retinal detachment; it can be associated with a wide spectrum of extraocular symptoms, such as auditory symptoms, and the most common condition is sensorineural hearing loss. Its etiology is recognized as a T-cell-mediated autoimmune response against melanocyte antigens present in the choroid, meninges, cochlea, and skin. Likewise, host genetic factors have been identified as predisposing for its development, specifically the presence of the HLA-DR4 allele, the HLA-DRB1 0405 subtype is the most studied up to date. Treatment is based on the administration of high doses of systemic corticosteroids, however, there is not much evidence that specifically evaluates the efficacy of these medications on their audiovestibular manifestations. This article presents a clinical case of VKH syndrome with concomitant hearing impairment and carries out a short narrative review of the literature.


REFERENCES

  1. Greco A, Fusconi M, Gallo A, Turchetta R, Marinelli C, MacriGF, et al. Vogt-Koyanagi-Harada syndrome. Autoimmun Rev. 2013;12(11):1033-8. doi: 10.1016/j.autrev.2013.01.004

  2. O’Keefe GA, Rao NA. Vogt-Koyanagi-Harada disease.Surv Ophthalmol. 2017;62(1):1-25. doi: 10.1016/j.survophthal.2016.05.002

  3. Sakata VM, da Silva FT, Hirata CE, de Carvalho JF, YamamotoJH. Diagnosis and classification of Vogt-Koyanagi-Haradadisease. Autoimmun Rev. 2014;13(4-5):550-5. doi: 10.1016/j.autrev.2014.01.023

  4. Lavezzo MM, Sakata VM, Morita C, Rodriguez EE, Abdallah SF,da Silva FT, et al. Vogt-Koyanagi-Harada disease: review of a rareautoimmune disease targeting antigens of melanocytes. Orphanet JRare Dis. 2016;11:29. doi: 10.1186/s13023-016-0412-4

  5. Mota L, Santos A. Síndrome de Vogt-Koyanagi-Harada e oseu acometimento multissistêmico. Rev. Assoc. Med. Bras.2010;56(5):590-95. doi: 10.1590/S0104-42302010000500023

  6. Radic B, Vukojevic N, Petelin Gadze Z, Dapic Ivancic B,Barun B. Vogt-Koyanagi-Harada syndrome: importance ofearly treatment. Acta Neurol Belg. 2020;120(5):1217-19. doi:10.1007/s13760-020-01273-x

  7. Noguchi Y, Nishio A, Takase H, Miyanaga M, Takahashi H,Mochizuki M, et al. Audiovestibular findings in patientswith Vogt-Koyanagi-Harada disease. Acta Otolaryngol.2014;134(4):339-44. doi: 10.3109/00016489.2013.868604

  8. Al Dousary S. Auditory and vestibular manifestations of Vogt-Koyanagi-Harada disease. J Laryngol Otol. 2011;125(2):138-41. doi: 10.1017/S0022215110001817

  9. Chan EW, Sanjay S, Chang BC. Headache, red eyes, blurred visionand hearing loss. Diagnosis: Vogt-Koyanagi-Harada syndrome.CMAJ. 2010;182(11):1205-9. doi: 10.1503/cmaj.082069

  10. Standardization of Uveitis Nomenclature (SUN) Working Group.Classification Criteria for Vogt-Koyanagi-Harada Disease. Am JOphthalmol. 2021;228:205-11. doi: 10.1016/j.ajo.2021.03.036

  11. Campos WR, Cenachi SPF, Soares MS, Gonçalves PF,Vasconcelos-Santos DV. Vogt-Koyanagi-Harada-like Diseasefollowing Yellow Fever Vaccination. Ocul Immunol Inflamm.2021;29(1):124-27. doi: 10.1080/09273948.2019.1661498

  12. Papasavvas I, Herbort CP Jr. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, followinganti-SARS-CoV-2 vaccination. J Ophthalmic Inflamm Infect.2021;11(1):21. doi: 10.1186/s12348-021-00251-5

  13. Ferreira MC, Matos IL, Mondelli MFCG. Audiologicalfindings in the Vogt-Koyanagi-Harada Syndrome.Codas. 2020;32(5):e20190183. Portuguese, English. doi:10.1590/2317-1782/20202019183

  14. Rodríguez Rivera V, Garrigues H, Pinazo R. Evolución de lahipoacusia neurosensorial bilateral en el síndrome de VogtKoyanagi Harada. Acta Otorrinolaringol Esp. 2011;62(6):465-68. doi: 10.1016/j.otorri.2010.09.002

  15. Pelosi S, Chandrasekhar SS. Intratympanic steroid use for hearingsalvage in Vogt-Koyanagi-Harada syndrome. Ear Nose ThroatJ. 2011;90(12):574-7. doi: 10.1177/014556131109001206

  16. Shivaram S, Nagappa M, Seshagiri DV, Shanthakumar JS,Panda SS, Anadure R, et al. Vogt-Koyanagi-Harada Syndrome- A Neurologist’s Perspective. Ann Indian Acad Neurol.2021;24(3):405-9. doi: 10.4103/aian.AIAN_405_20

  17. Lai TY, Chan RP, Chan CK, Lam DS. Effects of the durationof initial oral corticosteroid treatment on the recurrence ofinflammation in Vogt-Koyanagi-Harada disease. Eye (Lond).2009;23(3):543-8. doi: 10.1038/eye.2008.89

  18. Diallo K, Revuz S, Clavel-Refregiers G, Sené T, Titah C,Gerfaud-Valentin M, et al. Vogt-Koyanagi-Harada disease:a retrospective and multicentric study of 41 patients. BMCOphthalmol. 2020;20(1):395. doi: 10.1186/s12886-020-01656-x

  19. AlHelali N, Hajr E, Almuhawas F, Hagr A. Bilateral CochlearImplantation in Vogt-Koyanagi-Harada Syndrome: A CaseReport. Otol Neurotol. 2019;40(7):e694-97. doi: 10.1097/MAO.0000000000002262

  20. Sydlowski SA, Luffler C, Haberkamp T. Successfulcochlear implantation in a case of Vogt-Koyanagi-Haradadisease. Otol Neurotol. 2014;35(9):1522-4. doi: 10.1097/MAO.0000000000000353

  21. Morita S, Nakamaru Y, Obara N, Masuya M, Fukuda S.Characteristics and prognosis of hearing loss associatedwith Vogt-Koyanagi-Harada disease. Audiol Neurootol.2014;19(1):49-56. doi: 10.1159/000356386

  22. Ondrey FG, Moldestad E, Mastroianni MA, Pikus A, Sklare D,Vernon E, et al. Sensorineural hearing loss in Vogt-Koyanagi-Harada syndrome. Laryngoscope. 2006;116(10):1873-6. doi:10.1097/01.mlg.0000234946.31603.fe




2020     |     www.medigraphic.com